Cilostazol Eliminates Adverse Smoking Outcome in Patients With Drug-Eluting Stent Implantation-Analysis of Longer-Term Follow-up of the CILON-T Randomized Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hack-Lyoung | - |
dc.contributor.author | Suh, Jung-Won | - |
dc.contributor.author | Lee, Seung-Pyo | - |
dc.contributor.author | Kang, Hyun-Jae | - |
dc.contributor.author | Koo, Bon-Kwon | - |
dc.contributor.author | Cho, Young-Seok | - |
dc.contributor.author | Youn, Tae-Jin | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Choi, Dong-Ju | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Bae, Jang-Ho | - |
dc.contributor.author | Kwon, Taek-Geun | - |
dc.contributor.author | Bae, Jang-Whan | - |
dc.contributor.author | Cho, Myeong-Chan | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2021-09-05T08:25:06Z | - |
dc.date.available | 2021-09-05T08:25:06Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 1346-9843 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/98381 | - |
dc.description.abstract | Background: The present study investigated whether cilostazol can eliminate adverse smoking outcome after percutaneous coronary intervention (PCI). Methods and Results: A total of 914 patients with successful drug-eluting stent (DES) implantation were randomly assigned to dual antiplatelet therapy (DAT; aspirin and clopidogrel, n=457) or to triple antiplatelet therapy (TAT; DAT with cilostazol, n=457). The effect of smoking on 2-year major adverse cardio/cerebrovascular events (MACCE) in both the TAT and DAT groups was evaluated. Total MACCE were not significantly different between the 2 anti-platelet regimens (9.8% in TAT vs. 11.4% in DAT groups, P=0.45), but the adverse effects of smoking on clinical outcome were different between DAT vs. TAT. Current smokers had a higher prevalence of MACCE than non-smokers in the DAT group (16.7% vs. 9.5%, P=0.04). In the TAT group, however, the adverse effect of smoking was abolished (9.2% vs. 10.1%, P=0.85). Regarding the effects of smoking on the antiplatelet effects of DAT or TAT, post-treatment platelet reactivity (in P2Y12 reaction units; PRU) in current smokers was not significantly lower than that in non-smokers in the DAT group, whereas, in the TAT group, it was significantly lower than that of non-smokers (189 +/- 88 vs. 216 +/- 89 PRU, P=0.01). Conclusions: Adverse clinical effects of smoking may be eliminated by the addition of cilostazol to DAT after DES implantation. This may be due to the stimulation of cilostazol's antiplatelet effects by smoking. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | JAPANESE CIRCULATION SOC | - |
dc.subject | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject | TRIPLE ANTIPLATELET THERAPY | - |
dc.subject | ISCHEMIC VASCULAR COMPLICATIONS | - |
dc.subject | PLATELET REACTIVITY | - |
dc.subject | HEART-DISEASE | - |
dc.subject | METAANALYSIS | - |
dc.subject | CLOPIDOGREL | - |
dc.subject | RESTENOSIS | - |
dc.subject | EFFICACY | - |
dc.subject | IMPACT | - |
dc.title | Cilostazol Eliminates Adverse Smoking Outcome in Patients With Drug-Eluting Stent Implantation-Analysis of Longer-Term Follow-up of the CILON-T Randomized Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1253/circj.CJ-13-1394 | - |
dc.identifier.scopusid | 2-s2.0-84901335928 | - |
dc.identifier.wosid | 000336378000026 | - |
dc.identifier.bibliographicCitation | CIRCULATION JOURNAL, v.78, no.6, pp.1420 - U333 | - |
dc.relation.isPartOf | CIRCULATION JOURNAL | - |
dc.citation.title | CIRCULATION JOURNAL | - |
dc.citation.volume | 78 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1420 | - |
dc.citation.endPage | U333 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject.keywordPlus | TRIPLE ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | ISCHEMIC VASCULAR COMPLICATIONS | - |
dc.subject.keywordPlus | PLATELET REACTIVITY | - |
dc.subject.keywordPlus | HEART-DISEASE | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | RESTENOSIS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | Cilostazol | - |
dc.subject.keywordAuthor | Percutaneous coronary intervention | - |
dc.subject.keywordAuthor | Platelet function test | - |
dc.subject.keywordAuthor | Smoking | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.